Published in Breast Cancer Res Treat on September 21, 2007
Posttranscriptional regulation of cancer traits by HuR. Wiley Interdiscip Rev RNA (2010) 2.59
HuR function in disease. Front Biosci (Landmark Ed) (2012) 1.86
Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay. Ann Rheum Dis (2011) 1.54
Coordinated posttranscriptional mRNA population dynamics during T-cell activation. Mol Syst Biol (2009) 1.40
Minireview: global regulation and dynamics of ribonucleic Acid. Endocrinology (2010) 1.31
The RNA binding protein HuR differentially regulates unique subsets of mRNAs in estrogen receptor negative and estrogen receptor positive breast cancer. BMC Cancer (2010) 1.10
HDAC inhibitors regulate claudin-1 expression in colon cancer cells through modulation of mRNA stability. Oncogene (2009) 1.06
Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells. PLoS One (2013) 1.04
Epigenetic silencing of the human NOS2 gene: rethinking the role of nitric oxide in human macrophage inflammatory responses. J Immunol (2014) 0.96
Promoter- and cell-specific epigenetic regulation of CD44, Cyclin D2, GLIPR1 and PTEN by methyl-CpG binding proteins and histone modifications. BMC Cancer (2010) 0.96
Estrogen-mediated downregulation of CD24 in breast cancer cells. Int J Cancer (2008) 0.95
Nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) expression is increased by the histone deacetylase inhibitor trichostatin A. J Biol Chem (2008) 0.94
Genetic polymorphisms in RNA binding proteins contribute to breast cancer survival. Int J Cancer (2012) 0.88
5-aza-2'-deoxycytidine leads to reduced embryo implantation and reduced expression of DNA methyltransferases and essential endometrial genes. PLoS One (2012) 0.87
Manipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies? J Biomed Biotechnol (2010) 0.86
Post-transcriptional regulation of programmed cell death 4 (PDCD4) mRNA by the RNA-binding proteins human antigen R (HuR) and T-cell intracellular antigen 1 (TIA1). J Biol Chem (2014) 0.84
Neuroprotection requires the functions of the RNA-binding protein HuR. Cell Death Differ (2014) 0.84
HuR is necessary for mammary epithelial cell proliferation and polarity at least in part via ΔNp63. PLoS One (2012) 0.82
Fibronectin affects transient MMP2 gene expression through DNA demethylation changes in non-invasive breast cancer cell lines. PLoS One (2014) 0.81
Post-transcriptional controls by ribonucleoprotein complexes in the acquisition of drug resistance. Int J Mol Sci (2013) 0.80
Effects of physiological levels of the green tea extract epigallocatechin-3-gallate on breast cancer cells. Front Endocrinol (Lausanne) (2014) 0.78
5-Aza-2-deoxycytidine and trichostatin A increase COUP-TFII expression in antiestrogen-resistant breast cancer cell lines. Cancer Lett (2014) 0.75
Current Evidence and Future Perspectives on HuR and Breast Cancer Development, Prognosis, and Treatment. Neoplasia (2016) 0.75
Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells. Cancer Biol Ther (2008) 1.18
The RNA-binding protein HuR regulates GATA3 mRNA stability in human breast cancer cell lines. Breast Cancer Res Treat (2009) 0.83
Timing is everything: order of administration of 5-aza 2' deoxycytidine, trichostatin A and tamoxifen changes estrogen receptor mRNA expression and cell sensitivity. Cancer Lett (2008) 0.83
Inhibition of de novo purine synthesis in human prostate cells results in ATP depletion, AMPK activation and induces senescence. Prostate (2009) 0.76